VERSANIS BIO
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.
VERSANIS BIO
Industry:
Biotechnology Life Science Medical Pharmaceutical
Founded:
2021-01-01
Address:
Oakland, California, United States
Country:
United States
Website Url:
http://www.versanisbio.com
Total Employee:
11+
Status:
Active
Contact:
(617) 315-4410
Email Addresses:
[email protected]
Total Funding:
70 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon WordPress LetsEncrypt SSL By Default Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Aditum Bio
Aditum Bio investment in Series A - Versanis Bio
TCG Crossover
TCG Crossover investment in Series A - Versanis Bio
Medicxi
Medicxi investment in Series A - Versanis Bio
Atlas Venture
Atlas Venture investment in Series A - Versanis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-20 | Versanis Bio appoints Mark Pruzanski as CEO |
Official Site Inspections
http://www.versanisbio.com Semrush global rank: 6.95 M Semrush visits lastest month: 968
- Host name: ec2-18-188-128-145.us-east-2.compute.amazonaws.com
- IP address: 18.188.128.145
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Versanis Bio"
Versanis | Subsidiaries | Eli Lilly and Company
Versanis is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.See details»
Lilly to Acquire Versanis to Improve Patient Outcomes in ...
Jul 14, 2023 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Lilly to Acquire Versanis to Improve Patient Outcomes in ...
Jul 14, 2023 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Lilly Completes Acquisition of Versanis Bio
INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio.See details»
Versanis Bio - Crunchbase Company Profile & Funding
Aug 31, 2021 · Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio may be growing as it has been successfully acquired by …See details»
Lilly Completes Acquisition of Versanis Bio - PR Newswire
Aug 14, 2023 · For Versanis, Goodwin Procter LLP is acting as legal counsel, Cooley LLP is advising as to patent matters, and J.P. Morgan and Company is acting as financial advisor. …See details»
Lilly Completes Acquisition of Versanis Bio - Nasdaq
Aug 14, 2023 · Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of the upfront payment and subsequent payments upon …See details»
Versanis Bio Announces Leadership and Board Appointments as …
NEW YORK, July 20, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three …See details»
Eli Lilly to Acquire Versanis Bio in up to $1.925 Billion Deal With ...
Eli Lilly and Company and Versanis Bio have announced a definitive agreement for Lilly to pay up to $1.925 billion in cash to acquire Versanis Bio, a privately held, clinical-stage …See details»
Medicxi asset-centric portfolio company Versanis Bio to be …
Jul 14, 2023 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Lilly Completes Acquisition of Versanis Bio
Aug 14, 2023 · For Versanis,Goodwin Procter LLP is acting as legal counsel, patent matters, and J.P. Morgan and Company is acting as financial advisor. Lilly unites caring with discovery to …See details»
Lilly to Acquire Versanis to Improve Patient Outcomes in ...
Jul 14, 2023 · Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …See details»
Versanis Announces Initiation of the BELIEVE Global Phase 2b …
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today …See details»
Versanis Bio - Craft
Versanis Bio is a biotech company developing bimagrumab for the treatment of obesity in adults. It provide bimagrumab, a human monoclonal antibody to the activin type II receptors that block …See details»
Lilly to Acquire Versanis to Improve Patient Outcomes in ...
Jul 14, 2023 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Versanis Bio Announces $70 Million Series A Financing to Advance ...
Aug 31, 2021 · OAKLAND, Calif.-- (BUSINESS WIRE)-- Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of …See details»
Versanis Presents Preclinical Data Demonstrating the Potential of ...
Nov 2, 2022 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Versanis Bio to Present New Clinical Data at American Diabetes ...
Jun 23, 2023 · Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.See details»
Versanis Presents Data Demonstrating Bimagrumab Treatment …
NEW YORK, June 11, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, will share analysis of Phase 2 data …See details»